Immunotherapy has the potential to treat a wide variety of conditions, from autoimmune disease to cancer. However, the discovery of potential antibody therapeutics against key receptor proteins remains a major challenge for the traditional immunisation approaches currently available on the market. Twist Biopharma, an arm of Twist Bioscience, was built to overcome this bottleneck by […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!